

DAFTAR PUSTAKA

1. Cantour LB, Rapuano CJ, Cioffi GA. Thyroid Eye Disease. In: *Orbit, Eyelid, And Lacrimal System*. American Academy of Ophthalmology. 2019-2020. pp.53-62.
2. Joseph SS, Douglas RS. Thyroid Eye Disease: A Comprehensive Review. In: *Orbital Inflammatory Diseases and Their Differential Diagnosis*. Springer. 2015. pp.73-83.
3. Douglas RS. Graves' Eye Disease or Thyroid Eye Disease. In: <http://www.kellog.umich.edu/patientcare/graves.disease.html>. 2016. pp.1-3.
4. Mukasa K, Noh JY, Kouzaki A et al. TSH Receptor Antibody Titers Measured with a Third-generation Assay Did Not Reflect the Activity of Graves' Ophthalmopathy in Untreated Japanese Graves' Disease Patients. In: *Endocrine Journal Volume 63 Number 2*. 2015. pp.151-157.
5. Cantour LB, Rapuano CJ, Cioffi GA. Orbit. In: *Ophthalmic Pathology and Intraocular Tumors*. American Academy of Ophthalmology. 2015. pp.232-233.
6. Bhats R, Nelson CC, Douglas RS. Thyroid-associated Orbitopathy: Understanding Pathophysiology. In: *Saudi Journal of Ophthalmology Volume 25*. Elsevier. 2011. Pp.1-2.
7. Fajar JK, Hidayah CI, Zaini LM et al. Korelasi Derajat Graves' Ophthalmopathy dengan Durasi Menderita Hipertiroid. In: *CDK-228 Volume 42 No. 5*. 2015. pp.327-329.
8. Bartalena L. Prevention of Graves' Ophthalmopathy. In: *Best Practice & Research Clinical Endocrinology & Metabolism*. Elsevier. 2011. pp.371-377.
9. Iyer S, Bahn R. Immunopathogenesis of Graves' Ophthalmopathy: the Role of the TSH Receptor. In: *Best Pract Res Clin Endocrinol Metab*. 2012. pp.281-289.
10. Many MC, Costagliola S, Detrait M et al. Development of an Animal Model of Autoimmune Thyroid Eye Disease. In: *The Journal of Immunology*. The American Association of Immunologists. 1999. pp.4966-4974.
11. Barrio JB, Sabater AL, Farriol EB et al. Graves Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management. In: *Hindawi Publishing Corporation Journal of Ophthalmology*. 2015. pp.1-16.
12. Subekti I. Perbandingan Karakteristik Klinis, Kadar Hormon, dan Kadar Antibodi Reseptor TSH. In: *Oftalmopati Graves eJKI Volume 6 No. 1*. 2018. pp.33-37.
13. Sirmalinda. Hubungan antara Tekanan Intraokuler *Up gaze* dengan Derajat Beratnya Oftalmopati pada Penyakit Graves. In: *Tesis*. Padang. 2012. pp.1-65.
14. Rahayu I. Hubungan antara lama pemakaian propiltiourasil dengan perubahan derajat oftalmopati graves pada penyakit graves. In: *Tesis*. Padang. 2015. pp.9-66.

15. Kahaly GJ, Bartalena L, Hegedus L et al. 2018 European Thyroid Association Guidline for the management of Graves' Hyperthyroism. In: *European Thyroid Journal Volume 7*. Karger. 2018. pp.167-186.
16. Ludgate M, Baker G. Unlocking the Immunological Mechanisms of Orbital Inflammation in Thyroid Eye Disease. In: *Clin Exp Immunol Volume 127*. pp.193-198.
17. Kampmann E, Diana T, Kanitz M et al. Thyroid Stimulating but not Blocking Autoantibodies are Highly Prevalent in Severe and Active Thyroid-Associated Orbitopathy: A Prospective Study. In: *International Journal of Endocrinology*. 2015. pp.1-10.
18. Kahaly GJ. Diagnosis and Endocrine Management of Graves' Disease. In: *Thyroid Eye Disease*. Springer. Newyork. 2015. pp.1-7.
19. Subekti I, Boedisantoso A, Moeloek NDF et al. Association of TSH Receptor Antibody, Thyroid Stimulating Antibody, and Thyroid Blocking Antibody with Clinical Activity Score and Degree of Severity of Graves Ophthalmology. In: *The Indonesian Journal of Internal Medicine*. Acta Medica Indonesia. pp.114-120.
20. Takasu N, Yamashiro K, Ochi Y et al. TSBAb (TSH-Stimulation Blocking Antibody) in TSBAb-Positive Patienths with Hypothyroidism and Graves' Patients with Hyperthyroidism. In: *Horm Metab Res*. 2001. pp.232-237.
21. McAlinden C. An Overview of Thyroid Eye Disease. In: *Eye and Vision*. Biomed Central. 2014. pp.1-3.
22. Zophel K, Roggenbuck D, Wunderlich G et al. Continuosly Increasing Sensitivity Over Three Generation of TSH Receptor Autoantibody Assays. In: *Horm Metab Res Volume 42*. 2010. pp.900-902.
23. Medghalchi A, Akbari M, Alizadeh Y et al. The Epidemiological Characteristics of Patients with Thyroid Eye Disease in a Referral Center in Northern Iran. In: *Journal of Current Ophthalmology xx*. 2018. pp.1-5.
24. Nishikawa M, Yoshimura M, Toyoda N et al. Correlation of Orbital Muscle Changes Evaluated by Magnetic Resonance Imaging and Thyroid-stimulating Antibody in Patients with Graves' Ophthalmopathy. In: *Acta Endocrinologica*. 1993. pp.213-219.
25. Jang SY, Shin DY, Lee EJ et al. Correlation Between TSH Receptor Antibody Assays and Clinical Manifestations of Graves' Orbitopathy. In: *Yonsei Med J Volume 54 Number 4*. Korea. 2013. pp.1033-1039.
26. Thyroid Eye Disease. In: *Bringing American to Eye Care*, www.preventblindness.org/thyroid-eye-disease. 2019. pp.1-4.
27. Farida S, Sakti PT. Oftalmopati pada Penyakit Graves. In: *Jurnal Kedokteran* 5(3). 2016. pp.1-3.
28. Jang SY, Shin DY, Lee EJ et al. Relevance of TSH-receptor Antibody Levels in Predicting Disease Course in Graves' Orbitopathy: Comparison of the Third-Generation TBII Assay and Mc4-TSI Bioassay. In: *Eye Volume 27*. 2013. pp.964-971.

29. Tehrani MJ, Nabavi A, Kasaei A et al. Color Doppler Imaging in Thyroid Eye Disease and its Correlation to Disease Activity. In: *Orbit*. Taylor & Francis Group. 2019. pp.1-5.
30. Wang Y, Patel A, Douglas RS. Thyroid Eye Disease: How a Novel Therapy May Change the Treatment Paradigm. In: *Therapeutics and Clinical Risk Management*. Dovepress. 2019. pp.1305-1318.
31. Kim JM, Labree L, Levin L et al. The Relation of Graves' Ophthalmopathy to Circulating to Circulating Thyroid Hormone Status. In: *Br J Ophthalmol Volume 88*. 2004. Pp.72-74.
32. Asman P. Ophthalmological evaluation in thyroid-associated ophthalmopathy. *Acta Ophthalmologica Scandinavica* 2003;81:437-48.
33. Agrawal NK, Prakash V, Sharma M. Thyroid hormone Excess: Graves' Disease. In: <http://dx.doi.org/10.5772/47864>. 2012. pp.159-177.
34. Bucci I, Giuliani C, Napolitano G. Thyroid-Stimulating Hormone Receptor Antibodies in Pregnancy: Clinical Relevance. In: *Frontiers in Endocrinology*. 2017. pp.1-8.
35. King JR, Lachica R, Lee RH et al. Diagnosis and Management of Hyperthyroidism in Pregnancy: a Review. In: www.obgynsurvey.com. 2016. Pp.675-683.
36. Strianese D, Rossi F. Interruption of Autoimmunity for Thyroid Eye Disease: B-cell and T-cell Strategy. In: *The Royal College of Ophthalmologists*. Springer Nature. 2019. pp.1-7.
37. Wall JR, Lahooti H. Pathogenesis of Thyroid Eye Disease-Does Autoimmunity against the TSH Receptor Explain All Cases?. In: *Polish Journal of Endocrinology Volume 61 Number 2*. Australia. 2010. pp.222-227.
38. Weil D, Fridrich G. Graves Disease. In: *Orbita Tumors Diagnosis and Treatment*. Springer. 2005. pp.328-333.
39. Starkey KJ, Janezic A, Jones G et al. Adipose Thyrotropin Receptor Expression is Elevated in Graves' and Thyroid Eye Disease Ex vivo and Indicates Adipogenesis in Progress in Vivo. In: *Journal of Molecular Endocrinology Volume 30*. 2003. pp.369-380.
40. Kwon H, Kim WG, Jang EK et al. Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease. In: *Endocrinology and Metabolism Volume 31*. Korea. 2016. pp.300-309.
41. Lacheta D, Miskiewicz P, Gluszko A et al. Immunological Aspects of Graves' Ophthalmopathy. In: *Biomedical Research International*. 2019. pp.1-8.
42. Shibayama K, Ohyama Y, Yokota Y et al. Assays for Thyroid-stimulating Antibodies and Thyrotropin-binding Inhibitory Immunoglobulins in Children with Graves' Disease. In: *Endocrine Journal Volume 52 Number 5*. Japan. 2005. pp.505-510.
43. Yamano Y, Takamatsu J, Sakane S et al. Differences Between Changes in Serum Thyrotropin-Binding Inhibitory Antibodies and Thyroid-Stimulating Antibodies in the Course of Antithyroid Drug Therapy for Graves' Disease. In: *Thyroid*. 1999. pp.76-773.

44. Patel A, Yang H, Douglas RS. A New Era in the Treatment of Thyroid Eye Disease. In: *Ophthalmol.* Horizon Therapeutics. Elsevier. 2019. pp281-288.
45. Diana T, Kahaly GJ. Thyroid Stimulating Hormon Receptor Antibodies in Thyroid Eye Disease-Methodology and Clinical Applications. In: *Ophthalm Plast Reconstr Surg, Volume XX, Number XX.* 2018. pp.1-6.
46. Bluszcz GA, Bednarczuk T, Bartoszewicz Z et al. Clinical Utility of TSH Receptor Antibody Levels in Graves' Orbitopathy: a Comparison of Two TSH Receptor Antibody Immunoassays. In: *Central European Journal of Immunology Volume 43 Number 4.* 2018. pp.405-411.
47. Maugendre D, Massartf C. Clinical Value of a New TSH Binding Inhibitory Activity Assay Using Human TSH Receptors in the Follow-Up of Antithyroid Drug Treated Graves' Disease. Comparison with Thyroid Stimulating Antibody Bioassay. In: 2001. pp.89-96.
48. Wallaschofski H, Paschke R. Detection of Thyroid Stimulating (TSAB)- and Thyrotropin Stimalatin Blocking (TSBAB) Antibodies with CHO cell lines Expressing Different TSH-receptor Number. In: *Clinical Endocrinology.* 1999. pp.365-372.
49. Kazuo K, Fujkado T, Ohmi G et al. Value of Thyroid Stimulating Antibody in the Diagnosis of Thyroid Associated Ophthalmopathy of Euthyroid Patients. In: <http://bjournal.bmj.com/>. 2015. pp.1080-1083.
50. Hormann R, Saller B, Muller R et al. Prognostic Value of Thyroid Stimulating Antibodies and TSH-binding Inhibiting Immunoglobulins in the Follow-up of Graves' Disease. In: *Klinische Wochen-schrift.* Springer. 1985. pp.1247-1252.
51. Kashiwal T, Tada H, Asahi K et al. Significance of Thyroid Stimulating Antibody and Long Term Follow Up in Patients with Euthyroid Graves' Disease. In: *Endocrine Journal.* 1995. pp.405-412.
52. Elabscience. Human TSH-Ab (Thyroid Stimulating Hormone Antibody) ELISA Kit. 2019. Pp.1-11.
53. Kahaly GJ, Diana T. TSH Receptor Antibody Functionality and Nomenclature. In: *Frontiers in Endocrinology, Volume 8.* 2017. pp.1-2.
54. Dong Q, Liu X, Wang F et al. Dynamic Changes of TRAb and TPOAb after Radioiodine Therapy in Graves' Disease. In: *Acta Endocrinologica (Buc)* Volume 13 Number 1. 2017. Pp.72-76.
55. Ochi Y, Kajita Y, Hachiya T et al. Neutralization and Purification of Thyroid Stimulating Antibody (TSAb) and Thyroid Blocking Antibody (TBAb) by Heterophilic Antibody to Animal IgG in Graves' Disease. In: *Endocrine Journal.* 2012. pp.65-72.
56. Woo YJ, Jang SY, Taek Lim TY et al. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy. In: *Korean J Ophthalmol.* 2015. pp.2013-2018.
57. Shah Y. Thyroid Ophthalmopathy. In: *Suplement to JAPI, Volume 59.* 2011. pp.60-65.

58. Gerding MN, Jolanda WC, Broenik M et al. Association of Thyrotropin Receptor Antibodies with the Features of Graves' Ophthalmopathy. In: *Clinical Endocrinology Volume 52*. Netherlands. 2000. pp.267-271.
59. Tari AS, Tehrani MJ, Nabavi A et al. Effect of Smoking on Retrobulbar Blood Flow in Thyroid Eye Disease. In: *Eye*. 2016. pp.1-5.
60. Soh SB, Aw TC. Laboratory Testing in Thyroid Conditions-Pitfalls and Clinical Utility. In: *Annals of Laboratory Medicine Volume 39*. 2019. pp.3-14.
61. Bhats R, Nelson CC, Douglas RS. Thyroid-associated Orbitopathy: Currents insights into the Pathophysiology, Immunology, and Management. In: *Saudi Journal of Ophthalmology Volume 25*. Elsevier. 2011. pp.15-20.
62. Strianese D. Efficacy and Safety of Immunosuppressive Agent for Thyroid Eye Disease. In: *Ophthal Plast Reconstr Surg, Volume 34, Number 45*. 2018. pp.56-58.
63. Penta L, Muzi G, Cofini M et al. Corticosteroids in Moderate-to-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?. In: *International Journal of Environmental Research and Public Health*. 2019. pp.1-6.
64. Barbesino G, Tomer Y. Clinical Utility of TSH Receptor Antibodies. In: *Journal Clinical Endocrinol Metab Volume 98 Number 6*. 2013. pp.2247-2255.
65. Ochi Y, Kajita Y, Hachiya T et al. A Novel Hypothesis for the Etiology of Graves' Disease: TSAAb may be Thyroid Stimulating Animal IgG-like Hormone and TBAAb may be the Precursor of TSAAb. In: *Medical Hypotheses*. Elsevier. 2012. pp.781-786.
66. Dahlan MS. Konsistensi V Merencanakan Besar Sampel. In: *Langkah-langkah Membuat Proposal Penelitian Bidang Kedokteran dan Kesehatan*. Sagung Seto. Jakarta. 2010. pp.79-98.
67. Hussain YS, Hookham JC, Allahabadia A et al. Epidemiology, Management and Outcomes of Graves' Disease-Real Life Data. In: *Endocrine*. Springer. 2017. Pp.568-576.
68. Santin AP, Furlanetto TW. Role of Estrogen in Thyroid Function and Growth Regulation. In: *Journal of Thyroid Research*. 2011. pp.1-6.
69. Komiya I, Yamada T, Sato A et al. Remission and Recurrence of Hyperthyroid Graves' Disease during and after methimazole treatment when assessed by IgE and Interleukin 13. In: *The Journal of Clinical Endocrinology & Metabolism*. 2001. pp.2450-2454.
70. Wibowo RA, Wahyuningrum SN, Kusriani I et al. Autoimunitas Sebagai Faktor Risiko Hipertiroidisme pada Wanita Usia Subur di Daerah Replete Gangguan Akibat Kekurangan Iodium (GAKI). In: *MGMI Volume 9, No 2*. 2018. pp.139-145.
71. Stover EO, Kahaly G. Cellular Immunity and Retrobulbar Fibroblasts in Graves' Ophthalmopathy. In: *Thyroid Volume 4, Number 2*. 1994. pp.161-164.
72. Jurevic RJ, Chrisman P, Mancl L et al. Single-Nucleotide Polymorphisms and Haplotype Analysis in β -Defensin Genes in Different Ethnic Populations. In: *Genetic Testing Volume 6, Number 4*. 2002. pp.261-268.

73. Dowd JB, Palermo T, Chyu T et al. Race/Ethnic and Sosioeconomic Differences in Stress and Immune Function in The National Longitudinal Study of Adolescent Health. In: *Social Science & Medicine, Volume 115*. 2014. pp.49-55.
74. Weetman AP. Graves Diseases. In: *N Engl J Med Volume 343 Number 17*. 2000. pp. 1236-1248.
75. Wiersinga WM. Guidance in Subclinical Hyperthyroidism and Subclinical Hypothyroidism: Are We Making Progress?. In: *European Thyroid Journal*. 2015. pp.143-148.
76. Zulkarnain. Isolasi dan Karakteristik Fragmen Protein Human Thyroid Stimulating Hormone Receptor (hTSHR-169) Rekombinan untuk Mengenal Thyroid Stimulating Antibody (TSAb) pada Penderita Graves' Diseases. In: *Disertasi*. Malang. 2020. pp.1-126.

